E. Sun

发表

A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo

Alan S. Perelson, A. Perelson, D. Ho, 2003, Journal of Virology.

A Thorough QT Study To Evaluate the Effects of Therapeutic and Supratherapeutic Doses of Delafloxacin on Cardiac Repolarization

S. Cammarata, E. Sun, M. Thorn, 2015, Antimicrobial Agents and Chemotherapy.

Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study

S. Cammarata, J. Gardovskis, E. Sun, 2017, The Journal of antimicrobial chemotherapy.

Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia

D. Havlir, A. Zolopa, J. Gallant, 2002, Antimicrobial Agents and Chemotherapy.

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

G. Beall, M. Johnson, M. King, 2002, The New England journal of medicine.

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

Dale J. Kempf, John M. Leonard, Jacob J. Plattner, 1998, Antimicrobial Agents and Chemotherapy.

Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

R Rode, M Salgo, D. Ho, 1999, AIDS.

Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers

J. Leonard, A. Hsu, G. Granneman, 1998, Antimicrobial Agents and Chemotherapy.

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.

M. King, M. Witt, H. Kessler, 2004, The Journal of infectious diseases.

Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients

Richard A. Rode, Dale J. Kempf, D. Kempf, 2001, Journal of Virology.

The duration of viral suppression during protease inhibitor therapy for HIV‐1 infection is predicted by plasma HIV‐1 RNA at the nadir

J. Leonard, A. Molla, C. Boucher, 1998, AIDS.

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

A. D. Rodrigues, J. Leonard, A. Hsu, 1997, Antimicrobial agents and chemotherapy.

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir *

J. Leonard, A. Hsu, G. Granneman, 1998, Clinical pharmacology and therapeutics.

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

O. Ramilo, A. Hsu, D. Kempf, 2003, The Pediatric infectious disease journal.

Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.

A. Badley, A. Kumar, J. Angel, 2001, The Journal of infectious diseases.

Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir.

J. Leonard, A. Kumar, J. Angel, 1998, The Journal of infectious diseases.

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease

Calvin Cohen, John Leonard, Clement Maurath, 1998, The Lancet.

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.

C Maurath, R Rode, J. Leonard, 1998, Lancet.

Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.

A. Molla, D. Kempf, H. Mo, 2003, Antiviral research.

Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

A. Hsu, G. Granneman, D. Kempf, 2003, Antimicrobial Agents and Chemotherapy.

Determining the relative efficacy of highly active antiretroviral therapy.

Christine Hogan, Alan S Perelson, A. Perelson, 2003, The Journal of infectious diseases.

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.

A. Crook, Juliano Timm, P. Yablonskiy, 2022, The New England journal of medicine.

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

A. Hsu, D. Kempf, M. King, 2004, The Journal of infectious diseases.

Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.

J. Montaner, M. King, S. Brun, 2004, The Journal of infectious diseases.

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results

S. Hammer, A. Hsu, M. King, 2001, AIDS.

Safety, Tolerability, and Antiretroviral Effects of Ritonavir‐Nelfinavir Combination Therapy Administered for 48 Weeks

J. Gallant, C. Flexner, S. Eshleman, 2000, Journal of acquired immune deficiency syndromes.

Recent developments in HIV protease inhibitor therapy.

A. Molla, G. Granneman, D. Kempf, 1998, Antiviral research.

Metabolism and Disposition of the HIV-1 Protease Inhibitor Lopinavir (ABT-378) Given in Combination with Ritonavir in Rats, Dogs, and Humans

D. Kempf, H. Sham, K. Marsh, 2004, Pharmaceutical Research.

Modeling and Simulation of Effects of Adherence, Pharmacokinetic, and Pharmacodynamic Characteristics in Development of Resistance to HIV Regimens in Treatment-Naive Patients

A. Hsu, B. Poland, E. Sun, 2004 .

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.

P. Sax, A. Hsu, D. Kempf, 2002, The Journal of infectious diseases.

Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir Therapy

D. Kempf, M. King, S. Brun, 2001, Antiviral therapy.

Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.

S. Cammarata, E. Sun, S. Paulson, 2016, Clinical therapeutics.

Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.

S. Cammarata, E. Sun, S. Paulson, 2016, Clinical therapeutics.

RESULTS OF A GLOBAL PHASE 3 STUDY OF DELAFLOXACIN (DLX) COMPARED TO VANCOMYCIN WITH AZTREONAM (VAN) IN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI)

S. Cammarata, J. Gardovskis, E. Sun, 2015 .

Cost-Effectiveness of Lopinavir/Ritonavir Versus Nelfinavir As the First-Line Highly Active Antiretroviral Therapy Regimen for HIV Infection

S. Brun, K. Simpson, M. Luo, 2004, HIV clinical trials.

Genotypic Correlates of Reduced In Vitro Susceptibility to ABT-378 in HIV Isolates From Patients Failing Protease Inhibitor Therapy

K. Hertogs, B. Larder, D. Kempf, 1999 .

Assessment of the bioequivalence and food effects for liquid and soft elastic capsule co-formulations of ABT-378/ritonavir in healthy subjects

A. Hsu, R. Bertz, B. Bernstein, 2000 .

Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1beta.

A. Kumar, D. Kumar, J. Angel, 1999, AIDS research and human retroviruses.

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.

B. Larder, S. Bloor, J. Weber, 1999, AIDS research and human retroviruses.

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

A. Hsu, D. Kempf, M. King, 2004, The Journal of infectious diseases.